Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · NANOVIRICIDES, INC. (NNVC)

NanoViricides prices $3.8 million registered direct offering with warrants at $1.75

Mixed Impact 3 of 5 financing Written later

NanoViricides closed a registered direct offering on July 27, 2026, selling 2,416,339 common shares at $1.53 each, plus pre-funded warrants and common warrants, for approximately $3.8 million in gross proceeds before placement agent fees and expenses. The company intends to use the net proceeds for working capital, capital expenditures, research and development, clinical trials, and acquisitions and other strategic purposes. The sale adds shares and warrants that could dilute existing shareholders, and the company agreed to register the resale of the warrant shares.

Key points

  • Offering closed July 27, 2026; gross proceeds of approximately $3.8 million, before placement agent fees and offering expenses.
  • 2,416,339 common shares sold at $1.53 per share, plus pre-funded warrants for up to 100,000 shares at $1.52999 per warrant.
  • Common warrants for up to 2,516,339 shares at $1.75 per share, exercisable six months after issuance and expiring five and one-half years after issuance.
  • Placement agent D. Boral Capital LLC receives a 7.0% cash fee; the company must file a resale registration statement within 30 days after closing.

The filing

CompanyNANOVIRICIDES, INC. (NNVC)
Form8-K, current report
Filed with the SECJul 30, 2026, 6:02 AM ET
Accession number0001104659-26-088393

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.